# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001104659-26-040021
**Filing Date:** 2026-4
**Character Count:** 10178
**Document Hash:** b060134be2d776b03174c4fb6e78040d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-040021.hdr.sgml**: 20260406

**ACCESSION NUMBER**: 0001104659-26-040021

**CONFORMED SUBMISSION TYPE**: F-10POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260406

**DATE AS OF CHANGE**: 20260406

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980541667
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** F-10POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-140529
- **FILM NUMBER:** 26842176

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 4036707377

**MAIL ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**As filed with the U.S. Securities and Exchange Commission on April 6, 2026.**

**Registration Statement No. 333-140460**

**Registration Statement No. 333-140529**

**Registration Statement No. 333-151513**

**Registration Statement No. 333-167250**

**Registration Statement No. 333-182260**

**Registration Statement No. 333-197633**

**Registration Statement No. 333-224432**

**Registration Statement No. 333-239025**

**Registration Statement No. 333-265510**

**Registration Statement No. 333-281009**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-140460**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-140529**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-151513**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-167250**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-182260**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-197633**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-224432**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-239025**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-265510**<br> **POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-10 REGISTRATION STATEMENT NO. 333-281009**<br>**UNDER THE SECURITIES ACT OF 1933**<br>

ONCOLYTICS BIOTECH INC.

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **Nevada** | **98-0541667** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer Identification No.) |

---

**4350 Executive Drive, Suite 325<br> San Diego, California, 92121<br> (403) 670-7377**

(Address and Telephone number of Registrant's Principal Executive Offices)

**Jared Kelly**

**Chief Executive Officer**

**4350 Executive Drive, Suite 325**

**San Diego, California 92121**

**(403) 670-7377**

(Name, Address (including zip code) and Telephone Number (including Area Code) of Agent for Service in the United States)

*Copies to:*

**Christopher J. Clark, Esq.<br> Latham & Watkins LLP**<br> **555 Eleventh Street N.W., Suite 1000**<br> **Washington, D.C. 20004**<br> **(202) 637-2200**<br>

**Approximate date of proposed sale to the public**:<br> Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statements.

**Province of Alberta, Canada**

(Principal jurisdiction regulating this offering)

It is proposed that this filing shall become effective (check appropriate box):

A. ◻ Upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made
contemporaneously in the United States and Canada).

B. ◻ At some future date (check the appropriate box below):

&nbsp;&nbsp;&nbsp;&nbsp;1. ⌧ pursuant to Rule 467(b) on April 8, 2026 (date) at 4:30 p.m. Eastern time (time) (designate a time not
sooner than 7 calendar days after filing).

&nbsp;&nbsp;&nbsp;&nbsp;2. ◻ pursuant to Rule 467(b) on __(date) at ___(time) (designate a time 7 calendar days or sooner after filing)
because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ___(date).

&nbsp;&nbsp;&nbsp;&nbsp;3. ◻ pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or
the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with
respect hereto.

&nbsp;&nbsp;&nbsp;&nbsp;4. ◻ after the filing of the next amendment to this Form (if preliminary material is being filed).

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction's shelf prospectus offering procedures, check the following box. ◻

**EXPLANATORY NOTE**

This Post-Effective Amendment No. 2 to the Registration Statements (as defined below) is being filed solely to revise the designated effectiveness date and time under Rule 467(b) to April 8, 2026 at 4:30 p.m. Eastern time. No other changes have been made to the Registration Statements as previously amended.

**DEREGISTRATION OF SECURITIES**

These post-effective amendments relate to the following Registration Statements on Form F-10 (collectively, the "Registration Statements"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-140460) initially filed with the U.S. Securities and
Exchange Commission (the "SEC") by Oncolytics Biotech Inc. (the "Company") on [February 2, 2007](https://www.sec.gov/Archives/edgar/data/1129928/000113031907000052/o34619fv10.htm) and as amended,
pertaining to the registration of offers and sales by the Company of units ("Units");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-140529) initially filed with the SEC by the Company
on [February 8, 2007](https://www.sec.gov/Archives/edgar/data/1129928/000113031907000067/o34667fv10.htm) and as amended, pertaining to the registration of offers and sales by the Company of common shares ("Common
Shares");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-151513) initially filed with the SEC by the Company
on [June 6, 2008](https://www.sec.gov/Archives/edgar/data/1129928/000113031908000484/o40925fv10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Common Shares, subscription receipts,
warrants, Units (collectively "Securities") and debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-167250) initially filed with the SEC by the Company
on [June 2, 2010](https://www.sec.gov/Archives/edgar/data/1129928/000091228210000591/oncolytics_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-182260) initially filed with the SEC by the Company
on [June 21, 2012](https://www.sec.gov/Archives/edgar/data/1129928/000091228212000543/oncolytics_f10-june 2012.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-197633) initially filed with the SEC by the Company
on [July 25, 2014](https://www.sec.gov/Archives/edgar/data/1129928/000114420414044921/v384723_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-224432) initially filed with the SEC by the Company
on [April 25, 2018](https://www.sec.gov/Archives/edgar/data/1129928/000114420418022351/tv491991_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-239025) initially filed with the SEC by the Company
on [June 8, 2020](https://www.sec.gov/Archives/edgar/data/1129928/000110465920070925/tm2021919d1_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-265510) initially filed with the SEC by the Company
on [June 10, 2022](https://www.sec.gov/Archives/edgar/data/1129928/000110465922069752/tm2218106d1_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Registration Statement on Form F-10 (File No. 333-281009) initially filed with the SEC by the Company
on [July 25, 2024](https://www.sec.gov/Archives/edgar/data/1129928/000110465924082673/tm2419848d1_f10.htm) and as amended, pertaining to the registration of offers and sales by the Company of Securities.

The Company hereby withdraws the Registration Statements, including all amendments and exhibits thereto, with respect to the unsold portion of securities registered thereon.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused these post-effective amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 6th day of April, 2026.

---

| | |
|:---|:---|
| **ONCOLYTICS BIOTECH INC.** | **ONCOLYTICS BIOTECH INC.** |
| By: | /s/ Kirk Look |
|  | Kirk Look |
|  | Chief Financial Officer |

---

No other person is required to sign these post-effective amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.